<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003599</url>
  </required_header>
  <id_info>
    <org_study_id>DM97-078</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-97078</secondary_id>
    <secondary_id>NCI-P98-0132</secondary_id>
    <secondary_id>CDR0000066672</secondary_id>
    <nct_id>NCT00003599</nct_id>
  </id_info>
  <brief_title>Vitamin E in Preventing the Side Effects of Isotretinoin in Former and Current Smokers Who Are Receiving Isotretinoin to Prevent Lung Cancer</brief_title>
  <official_title>A Randomized Study of the Effect of Alpha-tocopherol (AT) on 13-cis-retinoic Acid (13-cRA) Toxicity in a Preliminary Chemoprevention Trial in Former and Current Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development or recurrence of cancer. The use of isotretinoin may be an effective way to&#xD;
      prevent lung cancer. Vitamin E may prevent the side effects of isotretinoin therapy.&#xD;
&#xD;
      PURPOSE: Randomized clinical trial to study the effectiveness of vitamin E in preventing the&#xD;
      side effects of isotretinoin in former and current smokers who are receiving isotretinoin to&#xD;
      prevent lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether the addition of alpha-tocopherol (AT; vitamin E) to&#xD;
      isotretinoin decreases the incidence of Grade II and higher toxicity of isotretinoin when&#xD;
      administered to former and current smokers. II. Determine the compliance rate of isotretinoin&#xD;
      of smoker and former smokers with or without AT over a six month period. III. Determine the&#xD;
      feasibility of recruiting former and current smokers with or without AT over a six month&#xD;
      period. IV. Determine the effect of isotretinoin administration on serum retinol and&#xD;
      retinol-binding protein levels in these patients.&#xD;
&#xD;
      OUTLINE: This is randomized, placebo controlled study. Patients are stratified by smoking&#xD;
      status (current smoker vs former smoker) and age (less than 50 vs 50 and over). Patients are&#xD;
      randomized to be take alpha-tocopherol (AT) orally and isotretinoin orally daily (arm I) or&#xD;
      isotretinoin orally plus AT placebo orally daily (arm II). Treatment in each arm continues&#xD;
      for 6 months. Patients are followed at 1, 3, 6, and 7 months from start of treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: There will be 300 patients (150 per arm) accrued into this study over an&#xD;
      estimated 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn study.&#xD;
  </why_stopped>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Alpha-tocopherol (AT) on 13-cis-retinoic Acid (13-cRA) Toxicity</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpha-tocopherol (AT) orally and isotretinoin orally daily (arm I)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isotretinoin orally plus AT placebo orally daily (arm II).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin E (AT)</intervention_name>
    <description>Orally daily</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>alpha-tocopherol</other_name>
    <other_name>AT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Orally daily</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Accutane</other_name>
    <other_name>13-cis-Retinoic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Current smokers with 20+ packs per year history of smoking OR&#xD;
        Former smokers who discontinued smoking 1 year prior to registration (less than 5&#xD;
        cigarettes in the prior year) and had a 20+ packs per year history prior to discontinuing&#xD;
        smoking&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life&#xD;
        expectancy: Not specified Hematopoietic: WBC greater than 3,000/mm3 Platelet count greater&#xD;
        than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL SGOT less than 40 IU/mL OR SGPT&#xD;
        less than IU/mL Renal: Not specified Other: Fasting triglycerides less than 320 mg/dL No&#xD;
        prior malignancy in the past 5 years except nonmelanoma skin cancer or noninvasive cervical&#xD;
        cancer No history of malabsorption syndrome Not pregnant Effective contraception required&#xD;
        of all fertile persons&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior&#xD;
        isotretinoin Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not&#xD;
        specified Other: No prior warfarin or its derivatives At least 3 months since megadose&#xD;
        vitamin A (greater than 25,000 IU/day) or beta-carotene greater than 30 mg/day or&#xD;
        alpha-tocopherol at least 400 IU daily No concurrent megadose vitamin A (greater than&#xD;
        25,000 IU/day), beta-carotene greater than 30 mg/day, alpha-tocopherol at least 400 IU&#xD;
        daily, or other daily supplements and tonics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodger J. Winn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2004</study_first_posted>
  <last_update_submitted>February 17, 2012</last_update_submitted>
  <last_update_submitted_qc>February 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

